Zoetis (NYSE:ZTS) Price Target Raised to $244.00

Zoetis (NYSE:ZTS) had its price target upped by Barclays from $242.00 to $244.00 in a report issued on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock.

ZTS has been the topic of a number of other reports. Piper Sandler cut their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Finally, Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $214.90.

Zoetis Stock Down 4.5 %

Zoetis stock opened at $157.54 on Friday. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a market cap of $71.08 billion, a PE ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90. The stock’s fifty day moving average is $168.51 and its two-hundred day moving average is $178.79.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. On average, sell-side analysts expect that Zoetis will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 37.59%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Zoetis

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after purchasing an additional 120,158 shares in the last quarter. State Street Corp boosted its holdings in Zoetis by 0.5% in the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after purchasing an additional 95,856 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Zoetis by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock valued at $1,726,075,000 after purchasing an additional 190,137 shares in the last quarter. Polen Capital Management LLC boosted its holdings in Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after purchasing an additional 1,116,541 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after acquiring an additional 3,059,255 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.